GSH attenuates RANKL-induced osteoclast formation in vitro and LPS-induced bone loss in vivo - 18/06/20
pages | 7 |
Iconographies | 6 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
GSH inhibits osteoclast differentiation by scavenging intracellular ROS and attenuating ROS-induced NF-κB signaling pathway.
Highlights |
• | GSH attenuates RANKL-induced osteoclastogenic and bone resorption in vitro. |
• | GSH inhibits NF-κB signaling by scavenging intracellular ROS during osteoclast differentiation. |
• | GSH prevents LPS-induced bone loss in vivo. |
Abstract |
Osteoclasts are capable of adhering the bone matrix, then secrete acid and lytic enzymes to resorb it. Reactive oxygen species (ROS), as a signaling messenger, plays an important role in the receptor activator nuclear factor κB ligand (RANKL) signal pathway during osteoclast differentiation. Glutathione (GSH) is known to be a powerful antioxidant which can scavenge intracellular ROS. This study aimed to investigate whether GSH can as a protective agent against the RANKL-stimulated osteoclastogenesis by suppressing intracellular ROS. Here, we showed that GSH markedly restricted RNAKL-induced differentiation of bone marrow-derived macrophages (BMMs) to form osteoclasts. GSH suppressed RANKL-induced ROS generation and subsequent ROS-induced NF-κB signaling pathways within BMMs during osteoclastogenesis. Further, GSH acted to significantly downregulate the osteoclastogenic genes expression of nuclear factor in activated T cells, cytoplasmic1 (NFATc1), C-fos, the tartrate-resistant acid phosphatase (TRAP), and osteoclast-associated immunoglobulin-like receptor (OSCAR). Our results suggested that GSH inhibits intracellular ROS-mediated NF-κB signal pathway involved in osteoclast differentiation. These findings might form the basis of a new strategy for treating bone disease associated with excessive bone resorption.
Le texte complet de cet article est disponible en PDF.Keywords : Glutathione, Bone loss, Differentiation, Reactive oxygen species
Plan
Vol 128
Article 110305- août 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?